CytoMed Therapeutics Limited announced that it signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co. Ltd. (CNK). With this agreement, CytoMed can utilize CNK's PiggyBac technology to permanently graft the Chimeric Antigen Receptor (CAR) gene into its gamma delta (?d) T cells via a non-viral gene editing method.

CytoMed was initially introduced to this opportunity by Professor Wang Shu, an advisor on the CytoMed Scientific Advisory Committee and co-inventor of the Company's CAR ?d T cell technology. Professor Wang Shu's deep understanding of cell therapy research, specifically CytoMed's technology, made it possible to discern the potential matching synergy between CytoMed and CNK's PiggyBac technologies. The MOU has a duration of one year, with the option to renew, and is subject to a definitive agreement and customary closing conditions.

There remains a potential opportunity for a joint venture to conduct clinical trials in China. The signing ceremony took place on August 15 at the 17th Singapore-Zhejiang Economic and Trade Council Meeting. In attendance was Senior Minister of State for National Development and Foreign Affairs Sim Ann and Zhejiang Vice Governor Lu Shan.